Intravenous infusions take 1–2 hours; most patients are discharged same-day with resumption of normal activity within 24 hours if tolerated. Temporary mild systemic reactions—malaise, low-grade fever—may occur within 48 hours. Gastrointestinal symptoms (bloating, altered bowel frequency) occasionally fluctuate in the first 1–2 weeks post-infusion. Therapeutic assessment requires 8–12 weeks as mucosal healing evolves gradually. No extended hospitalisation is typically needed.
Fourteen registered trials are examining stem cell or MSC-derived approaches in ulcerative colitis populations worldwide. A 2022 phase II study involving 41 UC patients receiving intravenous allogeneic placental MSCs showed clinical remission rates of 61% at week 12, versus 24% in the placebo arm. Endoscopic inflammation scores improved significantly in the treatment group. However, this trial lacked a blinded design, and a subsequent meta-analysis of 9 UC stem cell trials (total n=187) reported heterogeneous outcomes with clinical remission ranging 35–68%. No phase III trial data have been published. Mechanistic studies indicate tumour necrosis factor suppression and regulatory T-cell expansion.
Sono un candidato? → · Ulcerative Colitis: full overview → · Costo Colite Ulcerosa → · Cost →
Rivisto medicalmente dal team editoriale di StemCellAtlas con Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) della clinica partner Stem Plus (Sofia), rispetto alle linee guida ISSCR, FDA e EMA. Educational information, not medical advice; figures indicative.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita